Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

SgRNA cassette sequencing from H226 cells with doxycycline-inducible p63-targeting shRNA construct, treated with doxycycline for 14 days

ABSTRACT: sgRNA cassette sequencing from H226 cells with doxycycline-inducible p63-targeting shRNA construct, treated with doxycycline for 14 days

PROVIDER: PRJNA437574 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Similar Datasets

sgRNA cassette sequencing and RNA-seq from H226 cells expressing doxycycline-inducible Control (non-targeting) and p63-targeting shRNAs

Project description:sgRNA cassette sequencing and RNA-seq from H226 cells expressing doxycycline-inducible Control (non-targeting) and p63-targeting shRNAs

| PRJNA437621 | ENA

Poly(A)+ RNA-seq from H226 cells expressing doxycycline-inducible Control (non-targeting) and p63-targeting shRNAs

Project description:To determine the impact of ΔNp63α knockdown on steady-state mRNA levels, we performed poly(A)-enriched RNA-seq analysis of lung squamous cell carcinoma line H226 (inducible shControl and shp63) in the presence of 1µg/mL doxycycline to induce shRNA expression.

2018-08-27 | GSE111619 | GEO

Poly(A)+ RNA-seq from H226 cells expressing doxycycline-inducible Control (non-targeting) and p63-targeting shRNAs

Project description:Poly(A)+ RNA-seq from H226 cells expressing doxycycline-inducible Control (non-targeting) and p63-targeting shRNAs

| PRJNA437576 | ENA

sgRNA cassette sequencing from H226 cells with doxycycline-inducible p63-targeting shRNA construct, treated with doxycycline for 14 days

Project description:Genome-wide CRISPR/Cas9-based screen to identify anti-proliferative genes during ΔNp63α depletion

2018-08-27 | GSE111618 | GEO

sgRNA cassette sequencing and RNA-seq from H226 cells expressing doxycycline-inducible Control (non-targeting) and p63-targeting shRNAs

Project description:This SuperSeries is composed of the SubSeries listed below.

2018-08-27 | GSE111635 | GEO

Soil gene cassette metagenome

Project description:Integron gene cassette metagenome

| PRJNA485646 | ENA

Combining recombinase-mediated cassette exchange strategy with quantitative proteomic and phosphoproteomic analyses to inspect intracellular functions of the tumor supressor galectin-4 in colorectal cancer cells.

Project description:In order to systematically explore Galectin-4 function in CRC we established a CRC cell line where Gal4 expression can be regulated via doxycycline (dox)-inducible expression of a single copy wildtype LGALS4 transgene generated by recombinase-mediated cassette exchange (RMCE). Using this model and applying in depth proteomic and phosphoproteomic analyses we systematically screened for intracellular changes induced by Gal4 expression by.

2022-08-12 | PXD032902 | Pride

Chromatin modification is not a prerequisite for p63 binding but p63 binding can elicit chromatin remodeling

Project description:Transcription factor (TF) p63 is a master regulator playing critical roles in epidermal development and other cellular processes. Our lab’s previous research deciphered a distinct chromatin architecture at p63 bound site in keratinocytes. In order to figure out whether those chromatin modifications already exist before p63 binding, or p63 occupancy contributes to such chromatin marks, we built p63-expressing cell lines. We then obtained p63 bound regions in these overexpressing cell line, and looked at different histone marks at those sites before p63 occupancy. As shown in the results, before p63 binding, the targeting sites have barely detectable histone marks, indicating p63’s capability to approach unmodified chromatins. Moreover, there is no significant difference in chromatin marks between p63 bound sites and unbound sites when no p63 binding happens. Our in vivo findings were confirmed by examining p63 binding to unmodified nucleosomes in vitro, showing that histone modification is not indispensable for p63 binding but binding site positioning on nucleosome does play a role. Overall, our results suggest that histone modifications do not affect p63 binding, and p63 protein can bind to inaccessible, weakly modified chromatin regions in vivo.

2020-12-01 | GSE140329 | GEO

Identification of p63 binding regions in a p63 expressing basal-subtype breast cancer cell line, MCFDCIS.

Project description:p63 ChIP-SEQ in a p63 expressing basal-subtype breast cancer cell line, MCFDCIS and in a p63 deficient claudin-low subtype breast cancer cell line, MDA-MB-231 p63 ChIP-SEQ on MCFDCIS and MDA-MB-231 cell lines

2016-08-11 | E-GEOD-72009 | biostudies-arrayexpress

ChIP-seq of p63 and RNA-seq of knockdown and overexpression of p63

Project description:We performed ChIP-seq of p63 in ME-180 cell line and RNA-seq of knockdown and overexpression of p63

2019-08-06 | GSE135257 | GEO